LobbyingData.com Logo

Amgen, Inc. (AMGN) all U.S. Lobbying: all historical lobbying contracts, government bills & agencies, and critical issues lobbied on.


Discover Amgen, Inc.’s lobbying activities with our comprehensive dataset, offering insights on spending, bills, and issues from 1999-present. Analyze data by company, lobbyist, issue, and more through our intelligently crafted data design. Dataset updated weekly.


Using our intelligently designed and intuitive dataset, you can quickly understand how Amgen, Inc. (AMGN) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.

Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.

For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.

Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.

Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:

1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.

2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.

3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).

4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.

5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).

6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).

7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).

Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].

Frequently Asked Questions

What is Amgen, Inc. (AMGN) lobbying for?

Summary of Amgen’s lobbying data:

– Lobbying firms hired: The Mcmanus Group, Acg Advocacy, Bgr Government Affairs, Miller Strategies, Llp, Capitol Tax Partners, Amgen, Tarplin, Inc., Capitol Counsel Llc, Llc, The Nickles Group, Downs & Young, Akin Gump Strauss Hauer & Feld
– General issues they lobbied on: Taxation/Internal Revenue Code, Health Issues, Medicare/Medicaid, Copyright/Patent/Trademark, Trade (domestic/foreign), Budget/Appropriations
– Specific issues they lobbied on: Home Infusion, Issues related to DXA scans, Consolidated Appropriations Act, Public law 117-1769 Inflation Reduction Act HR 2617 Consolidated Appropriations Act of 2023 Issues related to drug pricing reform and Medicare Part D redesign S. 1943 and H.R. 3517, –FDA issues (Food and Drug Omnibus Reforms Act) –Issues related to Pharmacy Benefit Manger transparency –Issues related to clinical trial diversity S1435 affordable prescriptions for patients act H.R.2873 Affordable Prescriptions for Patients Through Promoting Competition Act H.R. 2884 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act Biosimilars reimbursement issues, –Issues related to FTC, FDASLA Act of 2022 and H.R. 7667, WTO/TRIPS waiver, S.1435 Affordable Prescriptions for Patients Act H.R.2873 Affordable Prescriptions for Patients Through Promoting Competition Act H.R. 2884 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S 2891 Restore the America Invents Act S. 2774 – Pride in Patent Ownership Act S. 4704 – Patent Examination and Quality Improvement Act of 2022 S. 4417 – Patent Trial and Appeal Board Reform Act of 2022 S. 4430 – Interagency Patent Coordination and Improvement Act of 2022 FTC related issues Issues related to the Patent Act Issues related to march-in/Bayh Dole, S3799 PREVENT Pandemics Act Issues related to cardiovascular disease awareness, Tax Cuts and Jobs Act Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income, no specific bill, 2023 340B, S. 2774, –issues related to cardiovascular disease, transparency, Part B, copay accumulators, Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, FDA issues, biosimilars, Medicare Part B Coverage and Reimbursement issues; Medicare Part D Coverage issues; and Medicare access to DXA services., 2023., Medicare Part D and Medicare Part B; H.R. 351
– Government agencies they lobbied: House of Representatives, Department of Treasury, Department of Health & Human Services (HHS), Senate, Centers For Medicare and Medicaid Services (CMS)

One could infer that Amgen is lobbying on a variety of issues related to healthcare, patent law, and taxation in order to protect their interests as a biopharmaceutical manufacturer. The specific lobbying issues related to drug pricing reform and Medicare Part D redesign suggest that Amgen wants to maintain their profitability in the face of potential changes to the regulatory landscape, while the patent-related issues suggest that they want to protect their intellectual property and ensure a favorable legal environment for biopharmaceutical companies. The lobbying on taxation issues and international negotiations may also be aimed at protecting Amgen’s profits and maintaining a competitive advantage in the global market.

Subscribe To Our Newsletter

gain actionable insights from our alternative data

More to explore